Raymond James Financial Services Advisors Inc. increased its position in Exelixis (NASDAQ:EXEL) by 41.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,817 shares of the biotechnology company’s stock after purchasing an additional 4,067 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Exelixis were worth $420,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC bought a new position in Exelixis in the third quarter worth $120,000. Sigma Planning Corp bought a new position in Exelixis in the fourth quarter worth $208,000. Klingenstein Fields & Co. LLC bought a new position in Exelixis in the fourth quarter worth $213,000. CIBC Asset Management Inc bought a new position in Exelixis in the third quarter worth $238,000. Finally, Crossmark Global Holdings Inc. bought a new position in Exelixis in the third quarter worth $239,000. 80.55% of the stock is owned by hedge funds and other institutional investors.
In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the completion of the transaction, the director now directly owns 64,829 shares in the company, valued at $1,964,318.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Patrick J. Haley sold 45,029 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $27.13, for a total value of $1,221,636.77. The disclosure for this sale can be found here. Insiders have sold 120,029 shares of company stock valued at $3,158,287 over the last quarter. Corporate insiders own 5.10% of the company’s stock.
Several research analysts recently commented on the company. BidaskClub cut Exelixis from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. TheStreet cut Exelixis from a “b” rating to a “c+” rating in a research report on Thursday. Zacks Investment Research cut Exelixis from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. Cann reaffirmed a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research report on Thursday, March 8th. Finally, Stifel Nicolaus raised their target price on Exelixis from $29.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. Exelixis presently has an average rating of “Hold” and a consensus target price of $34.10.
Exelixis (NASDAQ EXEL) opened at $24.64 on Friday. Exelixis has a 12 month low of $18.03 and a 12 month high of $32.50. The stock has a market capitalization of $7,301.00, a price-to-earnings ratio of 48.31, a price-to-earnings-growth ratio of 1.34 and a beta of 1.96.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The firm had revenue of $120.10 million during the quarter, compared to analyst estimates of $120.25 million. During the same period in the prior year, the company posted $0.12 earnings per share. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year. equities research analysts expect that Exelixis will post 0.57 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Raymond James Financial Services Advisors Inc. Raises Position in Exelixis (EXEL)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://ledgergazette.com/2018/03/18/raymond-james-financial-services-advisors-inc-raises-position-in-exelixis-exel.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.